增强磁共振血管成像及CT血管成像对早期宫颈癌供血血管的显示  

Comparison of contrast enhanced MR angiography and CT angiography in displaying blood supply of early stage cervical cancer

作　　者：雷李智 许乙凯[1] 侯美蓉 何梦琪[1] 

机构地区：[1]南方医科大学南方医院影像中心,广东广州510515

出　　处：《中国医学影像技术》2017年第8期1241-1245,共5页Chinese Journal of Medical Imaging Technology

摘　　要：目的对比增强磁共振血管成像(CE-MRA)和CTA对早期宫颈癌供血血管的显示效果。方法回顾性分析30例经病理证实为早期宫颈癌患者术前的CE-MRA和CTA图像,评估CE-MRA和CTA对双侧子宫动脉主干的起源及连续性显示的一致性,同时评估两者对子宫动脉下行支的显示率。结果 CE-MRA和CTA对子宫动脉主干起源显示清楚、血管显示清楚且连续性不中断为50支,子宫动脉主干起源显示清楚、血管显示不清楚为5支,CE-MRA和CTA对于子宫动脉的起源及连续性的显示一致性良好(Kappa=0.80,P<0.05)。MRA对子宫动脉下行支的显示率约为55.00%(33/60),低于CTA对子宫动脉下行支的显示率[73.33%(44/60)],差异有统计学意义(χ~2=26.22,P<0.01)。结论 CTA和CE-MRA均可良好地显示术前早期宫颈癌子宫动脉主干的起源及连续性,CTA对于早期宫颈癌患者子宫动脉下行支的显示较CE-MRA更具优势。Objective To compare the display effect of contrast enhanced MR angiography（CE-MRA）and CTA in evaluating blood supply of early stage cervical cancer.Methods CE-MRA and CTA before the operation of 30 patients with pathologically confirmed early stage cervical cancer were analyzed retrospectively.The origins and continuity of bilateral uterine arteries and the conspicuity of bilateral decending branch of uterine arteries between CE-MRA and CTA were evaluated.Results Fifty uterine arteries could classify as origins clearly visible and vessels clearly visible without discontinuity,5 uterine arteries as origins clearly visible but vessels unclearly visible on both CE-MRA and CTA.Both CE-MRA and CTA were conformed well in evaluating the origin and continuity of uterine arteries（Kappa=0.80,P〈0.05）.The conspicuity of decending branches for CE-MRA was 55.00%（33/60）,which was lower than that of CTA（73.33% [44/60]）,which had statistically significant difference between CE-MRA and CTA（χ2=26.22,P〈0.01）.Conclusion For early stage cervical cancer,CE-MRA and CTA can both provide a good performance in evaluating the origin and continuity of uterine arteries,CTA reveals advantage over CE-MRA in detecting conspicuity of decending branch of uterine arteries.

关 键 词：子宫颈肿瘤 子宫动脉 体层摄影术 X线计算机 磁共振成像 血管造影术 

分 类 号：R737.33[医药卫生—肿瘤] R445[医药卫生—临床医学]